CCT-ANK-11
/ Escure Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 11, 2024
CCT-ANK-11: An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Escure Biotechnology Corp | N=20 ➔ 0 | Recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Biliary Cancer • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
February 28, 2024
CCT-ANK-11: An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Escure Biotechnology Corp
New P1 trial • Biliary Cancer • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1